Iterion Therapeutics Revenue and Competitors

Location

$21.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Iterion Therapeutics's estimated annual revenue is currently $1M per year.(i)
  • Iterion Therapeutics's estimated revenue per employee is $77,500
  • Iterion Therapeutics's total funding is $21.4M.

Employee Data

  • Iterion Therapeutics has 13 Employees.(i)
  • Iterion Therapeutics grew their employee count by 8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M6200%N/AN/A
#2
$15.8M10234%N/AN/A
#3
$15.2M983%$1.8MN/A
#4
$2.8M18-25%N/AN/A
#5
$3.4M220%N/AN/A
#6
$2.6M1755%N/AN/A
#7
$7.6M4923%N/AN/A
#8
$0.9M6-33%N/AN/A
#9
$1.6M10-9%N/AN/A
#10
$1.1M7-42%N/AN/A
Add Company

Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/ -catenin signaling pathway, which is implicated in cell proliferation, differentiation, migration, apoptosis, immune evasion and stem cell renewal. Tegavivint has demonstrated pre-clinical in vivo efficacy in several cancer models, including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and multiple solid tumor types. The Company is enrolling a Phase I clinical study to evaluate safety and efficacy of Tegavivint in patients with desmoid tumors.

keywords:N/A

$21.4M

Total Funding

13

Number of Employees

$1M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Iterion Therapeutics News

2022-04-06 - Iterion Therapeutics Announces Presentation of Three Posters ...

HOUSTON, April 8, 2022 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.9M130%N/A
#2
$0.4M1318%$3M
#3
$1.9M13N/AN/A
#4
$1.1M13N/AN/A
#5
$1.7M13N/AN/A